Elacridar (Standaard)

Elacridar (Standard) is the analytical standard of Elacridar. This product is intended for research and analytical applications. Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer[1][2].

143664-11-3

12352100

H302, H315, H319, H335

BCRP; P-glycoprotein; Reference Standards

Membrane Transporter/Ion Channel; Others

Cancer

97.50

O=C1C2=CC=CC(C(NC(C=C3)=CC=C3CCN4CC(C=C(C(OC)=C5)OC)=C5CC4)=O)=C2NC6=C1C=CC=C6OC

C34H33N3O5

563.64

H302, H315, H319, H335

[1]Sane R, et al. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos. 2012 Aug;40 (8) :1612-9.|[2]Sato H, et al. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. Eur J Pharmacol. 2015 Jan 5;746:258-66.

Blue Ice

-20°C, sealed storage, away from light and moisture

http://file.medchemexpress.com/batch_PDF/HY-50879R/Elacridar-Standard-SDS-MedChemExpress.pdf

Reference Standards